Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 1,645 full-time employees. The company went IPO on 2016-05-09. The firm has diagnostic chains that conduct a range of medical diagnostic tests and profiles of tests that is focused on early detection and management of health disorders and diseases. The firm's segments include Diagnostic Testing Services, Imaging Services and Others. The Diagnostic Testing Services segment includes diagnostic and testing services, selling of consumables used for collection and promotion of pathology. The Imaging Services includes diagnostic and imaging services, selling of radio-pharmaceutical, selling of consumables for reporting. The Others segment include the sale of testing equipment and consumables, and selling of glucometer and glucostrips under the brand, Sugarscan. The firm has a centralized fully automated diagnostic testing laboratory, regional processing laboratories, a medical cyclotron facility and PET-CT facilities across India.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.